A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy
Public ClinicalTrials.gov record NCT04656561. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Masked, 4-Arm, Sham-Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) - The ARCHER Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is being conducted in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) to determine if intravitreal (IVT) injections of ANX007 reduce GA lesion growth rate. The results will be used to guide further development of ANX007 in participants with geographic atrophy. The total duration of participation is expected to be approximately 19 months.
Study identification
- NCT ID
- NCT04656561
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 270 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 26, 2021 (Actual)
- Primary completion
- Mar 28, 2023 (Actual)
- Completion
- Sep 13, 2023 (Actual)
- Last update posted
- Oct 21, 2026
2021 – 2023
United States locations
- U.S. sites
- 45
- U.S. states
- 19
- U.S. cities
- 42
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 5 | Phoenix | Arizona | 85053 | — |
| Site 31 | Bakersfield | California | 93309 | — |
| Site 2 | Beverly Hills | California | 90211 | — |
| Site 19 | Mountain View | California | 94040 | — |
| Site 23 | Pasadena | California | 91107 | — |
| Site 37 | Poway | California | 92064 | — |
| Site 17 | Sacramento | California | 95825 | — |
| Site 18 | Santa Ana | California | 92705 | — |
| Site 33 | Walnut Creek | California | 94598 | — |
| Site 39 | Waterford | Connecticut | 06385 | — |
| Site 12 | Fort Myers | Florida | 33907 | — |
| Site 53 | Jacksonville | Florida | 32216 | — |
| Site 26 | Pensacola | Florida | 32503 | — |
| Site 16 | Pinellas Park | Florida | 33782 | — |
| Site 43 | Sarasota | Florida | 34233 | — |
| Site 28 | St. Petersburg | Florida | 33711 | — |
| Site 6 | Winter Haven | Florida | 33880 | — |
| Site 42 | Augusta | Georgia | 30909 | — |
| Site 11 | Lexington | Kentucky | 40509 | — |
| Site 1 | Hagerstown | Maryland | 21740 | — |
| Site 41 | Hagerstown | Maryland | 21740 | — |
| Site 36 | Boston | Massachusetts | 02114 | — |
| Site 3 | Springfield | Massachusetts | 01107 | — |
| Site 29 | Royal Oak | Michigan | 48073 | — |
| Site 10 | Reno | Nevada | 89502 | — |
| Site 38 | Bloomfield | New Jersey | 07003 | — |
| Site 9 | Cherry Hill | New Jersey | 08034 | — |
| Site 30 | Albuquerque | New Mexico | 87109 | — |
| Site 20 | Asheville | North Carolina | 28803 | — |
| Site 52 | Cleveland | Ohio | 44195 | — |
| Site 13 | Edmond | Oklahoma | 73013 | — |
| Site 40 | Eugene | Oregon | 97401 | — |
| Site 27 | Philadelphia | Pennsylvania | 19107 | — |
| Site 15 | Abilene | Texas | 79606 | — |
| Site 4 | Austin | Texas | 78750 | — |
| Site 24 | Bellaire | Texas | 77401 | — |
| Site 34 | Burleson | Texas | 76028 | — |
| Site 21 | Dallas | Texas | 75231 | — |
| Site 32 | Fort Worth | Texas | 76102 | — |
| Site 22 | Fort Worth | Texas | 76104 | — |
| Site 35 | Katy | Texas | 77494 | — |
| Site 54 | San Antonio | Texas | 78240 | — |
| Site 8 | San Antonio | Texas | 78240 | — |
| Site 14 | Charlottesville | Virginia | 22903 | — |
| Site 25 | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04656561, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 21, 2026 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04656561 live on ClinicalTrials.gov.